Consonance Capital Partners Completes Recapitalization of Orsini Pharmaceutical Services in Partnership with Management Team
Middle-market health care investor Consonance Capital completed the recapitalization of Orsini, a specialty pharmacy focused on patients with rare diseases.
NEW YORK & ELK GROVE VILLAGE, Ill.–(BUSINESS WIRE)–Consonance Capital Partners, a leading healthcare-focused private equity fund, announced today that it completed the recapitalization of Orsini Pharmaceutical Services, LLC, (“Orsini” or the “Company”) in partnership with the Company’s CEO and President, Michael Fieri. Orsini is a leading rare disease specialty pharmacy differentiated by its personalized service and focus on complex conditions that require a high-touch patient journey. Financial terms of the transaction were not disclosed.
“Orsini’s mission is to improve the quality of life for patients living with difficult conditions,” commented Michael Fieri. “We partnered with Consonance not only because of their similar commitment to improving patient care but also as a result of their sector knowledge, extensive relationships, national reach, and their decades of healthcare investing experience more broadly. I am confident the additional resources this partnership brings will help us further expand our services and support our growth.”
“Consonance has long viewed specialty pharmacy as a sector uniquely positioned to improve outcomes through increased adherence and high-touch care coordination,” noted Stephen McKenna, Managing Partner & Co-Founder of Consonance Capital Partners. “Orsini is an exemplary model of how an innovative patient-centric approach and consistent culture of care can improve quality and lead to a strong value proposition for patients, manufacturers, and payors. We are excited to partner with Mike Fieri and the team to further expand their proven model of patient care targeting those who need it most.”
Javier Starkand, a Principal of Consonance Capital Partners, added, “At Consonance, we pride ourselves on investing in companies that improve lives and patient care, which is the reason we are excited to join Mike and the rest of the Orsini team. We have been thoroughly impressed with Orsini’s highly personalized approach to care and its reputation for innovation, data collection capabilities, and domain expertise in rare diseases, and we look forward to working with them as they continue to improve care for patients.”
Consonance Capital Partners was advised by Latham & Watkins LLP and Bass, Berry & Sims PLC. Orsini Pharmaceutical Services was advised by Barone Law Group P.C., Levenfeld Pearlstein, LLC, and Brown & Fortunato, P.C.
About Consonance Capital Partners
Consonance Capital Partners invests in private companies in the lower middle market of the U.S. healthcare industry with an emphasis on businesses driving efficiency, cost containment and high quality clinical care to patients. Consonance Capital Partners participates in growth equity, leveraged buyout, and recapitalization transactions. For more information, visit www.consonancecapital.com.
About Orsini Pharmaceutical Services
Orsini is a leading independent national specialty pharmacy focused on patients with rare and complicated diseases. Orsini’s services allow patients, physicians, payers and manufacturers to improve care, simplify processes and achieve better outcomes. The Company’s comprehensive solutions include nursing coverage nationwide for required in-home infusion services, data analytics, and medication adherence, among others. The Company distributes its products nationally under limited and exclusive distribution contracts with manufacturers. Based in Elk Grove Village, IL, Orsini has been accredited by URAC, VIPPS, ACHC, and JCAHO. For more information, visit www.orsinihealthcare.com.
